Outcomes of a Novel Penile Traction Device in Men with Peyronie’s Disease: A Randomized, Single-Blind, Controlled Trial
The DOI matches its Crossref record.
Abstract
PURPOSE: Current penile traction therapy devices have significant limitations, including the need to use them for 3 to 8 hours per day. Given these issues, the novel RestoreX® penile traction therapy device was developed in cooperation with Mayo Clinic. MATERIALS AND METHODS: We performed a randomized, controlled, single-blind, intent to treat trial (ClinicalTrials.gov NCT03389854) in men with Peyronie's disease who were assigned to the penile traction therapy device for 30 to 90 minutes per day or to no therapy for 3 months. Study inclusion criteria were curvature 30 degrees or greater with no study exclusions due to complex curvature, hourglass deformity, prior Peyronie's disease therapy or surgery, or calcification. The primary outcome was safety and secondary outcomes were penile length and curvature, and questionnaire responses. RESULTS: A total of 110 men were randomized 3:1 to the penile traction therapy group or the control group. The cohorts were well matched with a mean age of 58.4 years, a 49.7-month Peyronie's disease history and 59.3 degree curvature. Overall penile traction therapy was well tolerated with only transient and mild adverse events reported. At 3 months men undergoing penile traction therapy demonstrated significant improvements over controls in penile length (1.5 vs 0 cm, p <0.001), curvature (-11.7 vs 1.3 degrees, p <0.01) and erectile function (4.3 vs -0.7, p = 0.01) according to the International Index of Erectile Function-Erectile Function among men with erectile dysfunction. Overall 77% of the men on penile traction therapy experienced improved curvature (mean -17.2 degrees in 28.2% of responders) while 94% achieved increased length (1.6 cm in 10.9%). Counter bending and the white line indicator improved efficacy, validating key device innovations. Of men who had previously used other penile traction therapy devices 100% preferred the RestoreX device. CONCLUSIONS: Penile traction therapy with the RestoreX device for 30 to 90 minutes per day was safe, and resulted in significant and clinically meaningful improvements in penile curvature and length in men with Peyronie's disease, and in erectile function in men with erectile dysfunction and Peyronie's disease with no significant adverse events. To our knowledge these data represent the only reported improvements for any device used less than 3 to 8 hours per day.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Peyronie’s disease: Contemporary evaluation and management
Ziegelmann, M. J., Bajic, P., & Levine, L. A. (2020) · International Journal of Urology · doi:10.1111/iju.14230 · Cited by 86
Self-citationZiegelmann, M. J., Trost, L. W., Russo, G. I., & Levine, L. A. (2020) · The Journal of Sexual Medicine · doi:10.1016/j.jsxm.2019.11.271 · Cited by 31
Self-citationPeyronie’s disease: pharmacological treatments and limitations
Li, E. V., Esterquest, R., Pham, M. N., Panken, E. J., Amarasekera, C., Siebert, A., Bajic, P., & Levine, L. A. (2021) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2021.1903873 · Cited by 24
Non-surgical therapies for Peyronie’s disease
Rosenberg, J. E., Ergun, O., Hwang, E. C., Risk, M. C., Jung, J. H., Edwards, M. E., Blair, Y., & Dahm, P. (2023) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012206.pub2 · Cited by 14
Conservative Therapy for Peyronie’s Disease: a Contemporary Review of the Literature
Yousif, A., Natale, C., & Hellstrom, W. J. G. (2021) · Current Urology Reports · doi:10.1007/s11934-020-01024-8 · Cited by 12
Metadata
- Authors
- Ziegelmann, M., Savage, J., Toussi, A., Alom, M., Yang, D., Kohler, T., & Trost, L.
- Venue
- Journal of Urology
- Published
- 2019-09
- Volume
- 202
- Issue
- 3
- Pages
- 599-610
- ISSN
- 0022-5347 (ISSN-L)
- 1527-3792
- OpenAlex
- W2923883948
- Cited by
- 72
- References
- 0
- FWCI
- 7.38
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Outcomes of a Novel Penile Traction Device in Men with Peyronie’s Disease: A Randomized, Single-Blind, Controlled Trial. https://app.cochat.ai/papers/10.1097/ju.0000000000000245
- The paper
- Ziegelmann, M., Savage, J., Toussi, A., Alom, M., Yang, D., Kohler, T., & Trost, L. (2019). Outcomes of a Novel Penile Traction Device in Men with Peyronie’s Disease: A Randomized, Single-Blind, Controlled Trial. Journal of Urology. https://doi.org/10.1097/ju.0000000000000245
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.